| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 488 | FAB3628G-100 | |||
| Alexa Fluor 488 | FAB3628G-025 | |||
| Allophycocyanin | FAB3628A-100 | |||
| Allophycocyanin | FAB3628A-025 | |||
| Biotin | BAF3628 | |||
| Phycoerythrin | FAB3628P-100 | |||
| Phycoerythrin | FAB3628P-025 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF3628-SP | |||
| Carrier Free | FAB3628P-100 | |||
| Carrier Free | FAB3628P-025 | |||
| Carrier Free | FAB3628G-100 | |||
| Carrier Free | FAB3628G-025 | |||
| Carrier Free | FAB3628A-100 | |||
| Carrier Free | FAB3628A-025 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB4108-SP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 488 | FAB806G-100 | |||
| Biotin | BAF806 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF806-SP | |||
| Carrier Free | FAB806G-100 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF2777-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB27771-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-562SS | |||
| Azide and BSA Free | NBP2-80641 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | FAB3567P-100 | |||
| Carrier Free | FAB3567P-025 | |||
| Carrier Free | FAB3567F-100 | |||
| Carrier Free | FAB3567F-025 | |||
| Carrier Free | FAB3567A-100 | |||
| Carrier Free | FAB3567A-025 | |||
| Carrier Free | FAB3567N-100 | |||
| Carrier Free | FAB3567N-025 | |||
| Carrier Free | FAB3567C-100 | |||
| Carrier Free | FAB3567C-025 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-94011-0.02ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF3315-SP | |||
![Immunohistochemistry: Rabbit Polyclonal CD31/PECAM-1 Antibody [NB100-2284] - Staining of CD31 in human lung tissue. Nuclei in blue and CD31 (vessel) in green. Mouse anti-CD31 (1:100, overnight incubation at +4°C), followed by donkey anti-mouse 488 (1:400, 3h at RT). Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-2284_rabbit-polyclonal-cd31-pecam-1-antibody-immunohistochemistry-49202494658..jpg)
![Immunohistochemistry: CD31/PECAM-1 Antibody [NB100-2284] - Antibodies selected for characterization of stromal cells & vasculature in FFPE specimens are species-specific. (A, B) Labeling of a patient colon tumor (A) & Colo205 human cell line xenograft (B) with anti-human mitochondrial antibody (single arrow- tumor cells; double arrows- stroma). (C, D) Labeling of a patient pancreatic tumor (C) & Colo205 human cell line xenograft (D) with anti-human CD34. (E, F) Labeling of a patient lung tumor (E) & Colo205 xenograft (F) with anti-human CD31. (G, H) Labeling of a patient lung tumor (G) & Colo205 xenograft (H) with anti-mouse CD34. (bars = 50 μ). Image collected & cropped by CiteAb from the following publication (//translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-11-110), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2284_rabbit-cd31-pecam-1-pab-310202415371939.jpg)
![Immunohistochemistry: CD31/PECAM-1 Antibody [NB100-2284] - At the time of second passage, vessels in successfully growing xenografts of four different tumor types surveyed were of murine origin: A-C Colon; D-F Lung; G-I Pancreatic; J-L Renal Cell Carcinoma. For each tumor type, a representative section of an original patient specimen labeled with anti-huCD31 is shown (A, D, G, J). For each tumor, sections of the first passage xenografted tumor when it was resected are also shown; while no huCD31(+) vessels were identified in the xenografts (B, E, H, K), msCD34(+) vessels were abundant (C, F, I, L). (bars = 50 μ). Image collected & cropped by CiteAb from the following publication (//translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-11-110), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2284_rabbit-cd31-pecam-1-pab-3102024153970.jpg)
![Immunohistochemistry: CD31/PECAM-1 Antibody [NB100-2284] - Vascularization of an engrafted patient colon tumor. A patient colon tumor was implanted in a cohort of mice & vessel development was analyzed over 8 weeks. Vessels in the original patient specimen labeled strongly for huCD31 (A) & not for msCD34 (D). Representative sections showing loss of huCD31(+) vessels (B- 4 weeks, C- 7 weeks) & presence of msCD34(+) vessels (E- 4 weeks, F- 7 weeks) are shown. The graph (G) summarizes this process; huCD31(+) vessels were rapidly lost, & by one week, mouse vessels were the predominate vessels present in the colon tumors (no data for msCD34 at 2 weeks; bars = 100 μ). Image collected & cropped by CiteAb from the following publication (//translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-11-110), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2284_rabbit-cd31-pecam-1-pab-31020241535625.jpg)
![Western Blot: CD31/PECAM-1 Antibody [NB100-2284] - KCl pulse decreased membrane, but increased nuclear, detection of NHE1 in b.End3 endothelial cells.(A) Representative immunofluorescence images of bEnd.3 cells at two time-points after KCl or aCSF pulse. (B) Representative immunoblots of NHE1, alpha -tubulin, PECAM, & lamin B in cytosol, membrane, & nuclear fractions of bEnd.3 cells harvested at 5 min after KCl or aCSF pulse. (C = cytosol, M = membrane, N = nuclear) Values represent the mean ratio of NHE1 detection ± SEM (n = 11–12). (C) Representative immunoblots indicating NHE1 & alpha -tubulin as a loading control in whole cell lysate of bEnd.3 cells harvested at 5 min after KCl or aCSF pulse. Values represent the % of aCSF-treated relative expression ± SEM (n = 6). (D) Representative immunoblots of NHE1 & alpha -tubulin as a loading control in whole lysate of microvessels harvested at 90 min after cortical injection of KCl or aCSF. Values represent the % of naive relative expression ± SEM (n = 6). # denotes significantly different vs naïve (p<0.01), as assessed by one-way ANOVA (E) Intracellular pH during aCSF or KCl pulse. All data represent mean ± SEM (n = 45). (F) Extracellular pH during aCSF or KCl pulse. All data represent mean ± SEM (n = 6) in triplicate. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32469979), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2284_rabbit-cd31-pecam-1-pab-310202415541933.jpg)
![Immunocytochemistry/ Immunofluorescence: CD31/PECAM-1 Antibody [NB100-2284] - Impact of T‐AuNPs on endothelial cells in vivo. Immunofluorescent staining for endothelial cells using an anti‐CD 31 antibody revealed an intact endothelial cell monolayer in the uninjured control carotid artery (N = 3). As expected post balloon angioplasty, there is no endothelial cell monolayer of the injured left carotid arteries in the injury alone, injury + T‐AuNP, & injury + S‐AuNP treatment conditions. Green indicates autofluorescence of the elastic lamina. Magenta indicates endothelial cells. Images obtained using 25× magnification with exposure time of 400 msec. TUNEL staining for apoptosis revealed no evidence of endothelial cell apoptosis in the uninjured control carotid arteries, with a prominent endothelial cell monolayer (white arrowhead). Mild apoptosis was noted in the media of balloon‐injured left carotid arteries, as expected. Black arrows indicate apoptotic cells. Representative images obtained using 40× magnification. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28242820), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2284_rabbit-cd31-pecam-1-pab-3102024165737.jpg)
![Immunohistochemistry: CD31/PECAM-1 Antibody [NB100-2284] - The growth of a patient mesothelioma xenograft was supported by development of a murine vascular network. A patient mesothelioma was implanted in a cohort of mice & monitored for tumor growth. Once tumors began to actively grow, representative tumors were resected at weekly intervals & analyzed for vessel content. Staining for huCD31 was prominent in the original patient specimen (A), much reduced at 4 weeks (B) & negligible at 9 weeks (C). In contrast, patient specimens were not stained for msCD34 (D), whereas at 4 weeks large numbers of vessels stained for msCD34 (E) & by 9 weeks, msCD34 labeled vessels were predominant (F). The graph (G) summarizes the loss of detectable human vessels & acquisition of murine vessels over a 9 week period. (bars = 100 μ). Image collected & cropped by CiteAb from the following publication (//translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-11-110), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2284_rabbit-cd31-pecam-1-pab-31020241612684.jpg)
![Immunocytochemistry/ Immunofluorescence: CD31/PECAM-1 Antibody [NB100-2284] - TGF‐ beta 1 released by MSCs contributes to induced myofibroblast differentiation & granulation tissue formationA–C2.5 × 105 of TGF‐ beta 1 siRNA or control siRNA‐transfected AT‐MSCs were intradermally injected around each of CD18−/− murine wound. PBS mock injection served as negative control. Wound tissue was harvested at day 2, 5, & 7 post‐wounding for quantification of human TGF‐ beta 1 mRNA (A) at day 2 by qPCR, total TGF‐ beta 1 (B), & active TGF‐ beta 1 (C) protein at day 5 by ELISA. Data are expressed as mean ± SEM, n = 3 wounds per group, **P < 0.01, by one‐way ANOVA with Tukey's test.D–GExpression of alpha ‐SMA (D & E) & CD31 (F & G) at days 5 & 7 by immunostaining on tissue sections. The dashed lines indicate the border of the wound bed & epidermis or eschar. e, epidermis; es, eschar; wb, wound bed. Scale bars: 100 μm. Quantification data are expressed as mean ± SEM, n = 3 wounds per group, *P < 0.05, ***P < 0.001, by one‐way ANOVA with Tukey's test.Source data are available online for this figure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32080965), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2284_rabbit-cd31-pecam-1-pab-310202415532085.jpg)
![Immunocytochemistry/ Immunofluorescence: CD31/PECAM-1 Antibody (JC/70A) - BSA Free [NB600-562] - Immunohistochemial comparison of the expression of NMDAR1 on vessels & EndoMT markers in the urinary bladder.Biopsy specimens of frozen sections from the urinary bladders of (A, C, E) normal control subjects & (B, D, F) KC patients. (A, B) Double-immunofluorescence staining with antibody to endothelial marker CD31 (green) & NMDAR1 (red); DAPI was used as a nuclear stain (blue); co-expression of CD31 & NMDAR1 was evident in two groups (yellow, denoted by white arrows). (C–F) Double-immunofluorescence staining with antibody to endothelial marker CD31 (green) & two mesenchymal markers: FSP1 (red, in panels C & D) & alpha -SMA (red, in panels E & F); DAPI was used as a nuclear stain (blue); co-expression of CD31 & FSP1 or alpha -SMA was evident in three groups (yellow, denoted by white arrows) (white bars: 50 μm). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27529746), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-562_mouse-monoclonal-cd31-pecam-1-antibody-jc-70a-310202416171426.jpg)
![Immunocytochemistry/ Immunofluorescence: CD31/PECAM-1 Antibody (JC/70A) - BSA Free [NB600-562] - Immunohistochemial comparison of the expression of NMDAR1 on vessels & EndoMT markers in the urinary bladder.Biopsy specimens of frozen sections from the urinary bladders of (A, C, E) normal control subjects & (B, D, F) KC patients. (A, B) Double-immunofluorescence staining with antibody to endothelial marker CD31 (green) & NMDAR1 (red); DAPI was used as a nuclear stain (blue); co-expression of CD31 & NMDAR1 was evident in two groups (yellow, denoted by white arrows). (C–F) Double-immunofluorescence staining with antibody to endothelial marker CD31 (green) & two mesenchymal markers: FSP1 (red, in panels C & D) & alpha -SMA (red, in panels E & F); DAPI was used as a nuclear stain (blue); co-expression of CD31 & FSP1 or alpha -SMA was evident in three groups (yellow, denoted by white arrows) (white bars: 50 μm). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27529746), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-562_mouse-monoclonal-cd31-pecam-1-antibody-jc-70a-31020241618941.jpg)
![Immunocytochemistry/ Immunofluorescence: CD31/PECAM-1 Antibody (JC/70A) - BSA Free [NB600-562] - Immunohistochemial comparison of the expression of NMDAR1 on vessels & EndoMT markers in the urinary bladder.Biopsy specimens of frozen sections from the urinary bladders of (A, C, E) normal control subjects & (B, D, F) KC patients. (A, B) Double-immunofluorescence staining with antibody to endothelial marker CD31 (green) & NMDAR1 (red); DAPI was used as a nuclear stain (blue); co-expression of CD31 & NMDAR1 was evident in two groups (yellow, denoted by white arrows). (C–F) Double-immunofluorescence staining with antibody to endothelial marker CD31 (green) & two mesenchymal markers: FSP1 (red, in panels C & D) & alpha -SMA (red, in panels E & F); DAPI was used as a nuclear stain (blue); co-expression of CD31 & FSP1 or alpha -SMA was evident in three groups (yellow, denoted by white arrows) (white bars: 50 μm). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27529746), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-562_mouse-monoclonal-cd31-pecam-1-antibody-jc-70a-310202416173525.jpg)
![Immunocytochemistry/ Immunofluorescence: CD31/PECAM-1 Antibody (JC/70A) - BSA Free [NB600-562] - Immunohistochemial comparison of the expression of NMDAR1 on vessels & EndoMT markers in the urinary bladder.Biopsy specimens of frozen sections from the urinary bladders of (A, C, E) normal control subjects & (B, D, F) KC patients. (A, B) Double-immunofluorescence staining with antibody to endothelial marker CD31 (green) & NMDAR1 (red); DAPI was used as a nuclear stain (blue); co-expression of CD31 & NMDAR1 was evident in two groups (yellow, denoted by white arrows). (C–F) Double-immunofluorescence staining with antibody to endothelial marker CD31 (green) & two mesenchymal markers: FSP1 (red, in panels C & D) & alpha -SMA (red, in panels E & F); DAPI was used as a nuclear stain (blue); co-expression of CD31 & FSP1 or alpha -SMA was evident in three groups (yellow, denoted by white arrows) (white bars: 50 μm). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27529746), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-562_mouse-monoclonal-cd31-pecam-1-antibody-jc-70a-31020241616378.jpg)
![Immunocytochemistry/ Immunofluorescence: CD31/PECAM-1 Antibody (JC/70A) - BSA Free [NB600-562] - Immunohistochemial comparison of the expression of NMDAR1 on vessels & EndoMT markers in the urinary bladder.Biopsy specimens of frozen sections from the urinary bladders of (A, C, E) normal control subjects & (B, D, F) KC patients. (A, B) Double-immunofluorescence staining with antibody to endothelial marker CD31 (green) & NMDAR1 (red); DAPI was used as a nuclear stain (blue); co-expression of CD31 & NMDAR1 was evident in two groups (yellow, denoted by white arrows). (C–F) Double-immunofluorescence staining with antibody to endothelial marker CD31 (green) & two mesenchymal markers: FSP1 (red, in panels C & D) & alpha -SMA (red, in panels E & F); DAPI was used as a nuclear stain (blue); co-expression of CD31 & FSP1 or alpha -SMA was evident in three groups (yellow, denoted by white arrows) (white bars: 50 μm). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27529746), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-562_mouse-monoclonal-cd31-pecam-1-antibody-jc-70a-3102024161609.jpg)
![Immunocytochemistry/ Immunofluorescence: CD31/PECAM-1 Antibody (JC/70A) - BSA Free [NB600-562] - Immunohistochemial comparison of the expression of NMDAR1 on vessels & EndoMT markers in the urinary bladder.Biopsy specimens of frozen sections from the urinary bladders of (A, C, E) normal control subjects & (B, D, F) KC patients. (A, B) Double-immunofluorescence staining with antibody to endothelial marker CD31 (green) & NMDAR1 (red); DAPI was used as a nuclear stain (blue); co-expression of CD31 & NMDAR1 was evident in two groups (yellow, denoted by white arrows). (C–F) Double-immunofluorescence staining with antibody to endothelial marker CD31 (green) & two mesenchymal markers: FSP1 (red, in panels C & D) & alpha -SMA (red, in panels E & F); DAPI was used as a nuclear stain (blue); co-expression of CD31 & FSP1 or alpha -SMA was evident in three groups (yellow, denoted by white arrows) (white bars: 50 μm). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27529746), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-562_mouse-monoclonal-cd31-pecam-1-antibody-jc-70a-310202416163753.jpg)
![Immunocytochemistry/ Immunofluorescence: CD31/PECAM-1 Antibody (JC/70A) - BSA Free [NB600-562] - Immunohistochemial comparison of the expression of NMDAR1 on vessels & EndoMT markers in the urinary bladder.Biopsy specimens of frozen sections from the urinary bladders of (A, C, E) normal control subjects & (B, D, F) KC patients. (A, B) Double-immunofluorescence staining with antibody to endothelial marker CD31 (green) & NMDAR1 (red); DAPI was used as a nuclear stain (blue); co-expression of CD31 & NMDAR1 was evident in two groups (yellow, denoted by white arrows). (C–F) Double-immunofluorescence staining with antibody to endothelial marker CD31 (green) & two mesenchymal markers: FSP1 (red, in panels C & D) & alpha -SMA (red, in panels E & F); DAPI was used as a nuclear stain (blue); co-expression of CD31 & FSP1 or alpha -SMA was evident in three groups (yellow, denoted by white arrows) (white bars: 50 μm). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27529746), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-562_mouse-monoclonal-cd31-pecam-1-antibody-jc-70a-310202416171483.jpg)
![Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis using the FITC conjugate of CD31/PECAM-1 Antibody (TLD-3A12) (NB100-64796). Staining of rat brain cryosection with Mouse.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Immunohistochemistry-Frozen-NB100-64796-img0012.jpg "Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis using the FITC conjugate of CD31/PECAM-1 Antibody (TLD-3A12) (NB100-64796). Staining of rat brain cryosection with Mouse.")
![Flow Cytometry: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis using the Alexa Fluor (R) 488 conjugate of CD31/PECAM-1 Antibody (TLD-3A12) (NB100-64796). Staining of PBMC's (Monocyte gate at 1 x 10^6 cells/ml) with CD31 antibody (orange) stained at a dilution of 1:500. Shown with mIgG (AF488) isotype control (blue).](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Flow-Cytometry-NB100-64796-img0007.jpg)
![Immunohistochemistry-Paraffin: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis of CD31 in 4th day cutaneous wound section of diabetic rat using CD31/PECAM-1 Antibody (TLD-3A12). Image from verified customer review.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Immunohistochemistry-Paraffin-NB100-64796-img0005.jpg)
![Immunohistochemistry-Frozen: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - Analysis using the FITC conjugate of CD31/PECAM-1 Antibody (TLD-3A12) (NB100-64796). Staining of rat spleen cryosection.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Immunohistochemistry-Frozen-NB100-64796-img0013.jpg)
![Immunohistochemistry-Paraffin: CD31/PECAM-1 Antibody (TLD-3A12) [NB100-64796] - IHC analysis for the expression of CD31 of wound tissues of different groups of rats (magnification 200). n = 6, **P less than 0.01. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/sci/2019/9564869/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD31-PECAM-1-Antibody-TLD-3A12-Immunohistochemistry-Paraffin-NB100-64796-img0014.jpg)
![Western Blot: OBCAM/OPCML Antibody [NBP2-94011] - Analysis of extracts of various cell lines, using OBCAM/OPCML at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit .Exposure time: 10s.](http://images.novusbio.com/fullsize/OBCAM-OPCML-Antibody-Western-Blot-NBP2-94011-img0001.jpg "Western Blot: OBCAM/OPCML Antibody [NBP2-94011] - Analysis of extracts of various cell lines, using OBCAM/OPCML at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit .Exposure time: 10s.")
